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Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear
association with tumour progression and immuno-escape has not been established. FasL plays an important role in promoting tumour
cells’ ability to counterattack immune cells. Here, we examined immunohistochemically the expression of CRH, CRHR1, CRHR2 and
FasL in 47 human ovarian cancer cases. The ovarian cancer cell lines OvCa3 and A2780 were further used to test the hypothesis that
CRH might contribute to the immune privilege of ovarian tumours, by modulating FasL expression on the cancer cells. We found that
CRH, CRHR1, CRHR2 and FasL were expressed in 68.1, 70.2, 63.8 and 63.8% of the cases respectively. Positivity for CRH or FasL
expression was associated with higher tumour stage. Finally, CRH increased the expression of FasL in OvCa3 and A2780 cells
through CRHR1 thereby potentiated their ability to induce apoptosis of activated peripheral blood lymphocytes. Corticotropin-
releasing hormone produced by human ovarian cancer might favour survival and progression of the tumour by promoting its immune
privilege. These findings support the hypothesis that CRHR1 antagonists could potentially be used against ovarian cancer.
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Epithelial ovarian cancer causes more deaths than any other
gynaecologic cancer mainly because it is diagnosed at an advanced
stage and more than half of patients have remission after surgical
debulking and primary chemotherapy. Ovarian carcinoma may be
recognised and attacked by the immune system. It has been
reported that the presence of intratumoral T cells correlate with
improved clinical outcome in advanced ovarian carcinoma (Zhang
et al, 2003).
Peripheral corticotropin-releasing hormone (CRH) has been
detected in ovarian carcinoma (Suda et al, 1986). Thereafter, CRH
and its receptors have been localised in a number of tumours, but
the role of the neuropeptide in the biology of cancer is still unclear
(Ciocca et al, 1990; Sato et al, 2002; Reubi et al, 2003). Evidence
for an anti-proliferative effect of CRH in human endometrial
adenocarcinoma cells as well as in human and rat mammary
cancer cells has been reported (Tjuvajev et al, 1998; Graziani et al,
2002, 2007).
The proapoptotic molecule Fas ligand (FasL) is stored in the
intracellular granules of T and NK cells and can be delivered to the
cell surface upon non-specific activation of these cells (Bossi and
Griffiths, 1999). FasL binds to its receptor Fas and induces apoptosis
of the Fas-bearing cell. FasL is also produced by non-immune cells,
such as Sertoli cells in the testis, corneal endothelium and epithelium
of the eye, extravillous trophoblasts (EVT) at the implantation site
and several types of tumour cells (Bellgrau et al, 1995; Suda et al,
1995; Griffith et al, 1996; Makrigiannakis et al, 2001; O’Connell et al,
2001). In these cases, FasL attacks activated Fas-expressing immune
cells, and is therefore crucial for the immune privilege of the tissues
expressing it.
We have previously reported that CRH acts on EVT through
CRHR1 to upregulate FasL expression and thus potentiate the ability
of the cells to kill activated maternal T lymphocytes (Makrigiannakis
et al, 2001). Corticotropin-releasing hormone has also been shown to
upregulate the expression of FasL in PC12 rat pheochromocytoma
cells, by activating CRHR1 (Dermitzaki et al, 2002).
In the present study, we examined the distribution of CRH,
CRHR1, CRHR2 and FasL peptides in ovarian carcinoma and we
investigated the potential role of CRH and FasL in modulating the
immune defenses of ovarian cancer cells.
MATERIALS AND METHODS
Immunohistochemistry
The tissue material (47 cases of ovarian cancer, of which 10 were
stage II, 25 were stage III and 12 were stage IV) was selected
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sfollowing histological review from the files of the Hellenic
Cooperative Oncology Group (HeCOG). This study was approved
by the Ethical Committee of the Medical School, University of
Ioannina, Ioannina. For immunohistochemistry, serial sections of
4–6mm were deparaffinised in xylene and rehydrated in graded
alcohol to TBS (50mM Tris, 150mM NaCl, pH 7.4). The latter was
used for washes between steps. The slides were microwaved for
4 5min in 10mM citrate, pH 6.0. After cooling down for 20min,
the slides were blocked for 30min at room temperature (rt) with
normal serum (rabbit IgG, ABC Kit, Vector Laboratories,
Burlingame, CA, USA), diluted 1:20 and then incubated with one
of the primary antibodies (CRH antibody was obtained from
Phoenix Pharmaceuticals, Burlingame, CA, USA and Corticotropin-
releasing hormones like CRHR1, CRHR2 and FasL antibodies were
obtained from Santa Cruz, CA, USA) overnight in a dilution 1/100
in TBS plus 2% bovine serum albumin (BSA). The slides were then
incubated with the appropriate biotinylated secondary antibody
(BioGenex, San Ramon, CA, USA) for 20min at rt. Finally, the
slides were incubated for 20min with streptavidin-conjugated
horseradish peroxidase (BioGenex) and the peptides were localised
using 3,30-diaminobenzidine tetrahydrochloride as chromogen
(BioGenex). Tissues were counterstained with haematoxylin
(BioGenex), mounted with coverslips and photographed with a
Nikon digital camera, Tokyo, Japan under an Olympus microscope,
Olympus Optical Co, Tokyo, Japan.
The intensity and distribution patterns of the staining reaction
were evaluated by two blinded, independent observers, including a
gynaecological pathologist, using the semiquantitative immuno-
reactive score (IRS), as described previously (Remmele et al, 1986).
The IRS was calculated by multiplication of optical staining
intensity (graded as 0¼no, 1¼weak, 2¼moderate and 3¼strong
staining) and the percentage of positive-stained cells (0¼no
staining, 1¼o10% of the cells, 2¼11–50% of the cells, 3¼51–
80% of the cells and 4¼481% of the cells) and without having
knowledge of the pathological evaluation, the diagnosis or the
standard performed haematoxylin reaction of each specimen.
Cell lines
The OvCa3 and A2780 ovarian cancer cell lines were used for the
in vitro experiments. The cells were kept in DMEM (GibcoBRL,
Gaithersburg, MD, USA) supplemented with 10% FCS (GibcoBRL)
and antibiotics. The cells were kept in incubators at 371C and
5% CO2.
RT–PCR
Total RNA was extracted from cultures of OvCa3 and A2780 cells
using the RNA extraction II kit (Molecular Probes, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Five micro-
grams of total RNA were reverse-transcripted using a reverse
transcription kit (Invitrogen Life Technologies, Carlsbad, CA,
USA). An aliquot of 1/20th of the resulting cDNA was used for PCR
amplification using the appropriate kit according to the manu-
facturer’s instructions (Invitrogen Life Technologies).
For CRH, primers were: sense 50-CAACTTTTTCCGCG
TGTTGCT-30,a n t i s e n s e5 0-ATGGCATAAGAGCAGCGCTAT-30,w h i c h
amplified a fragment of 248bp. The PCR conditions consisted of
an initial denaturing step of 981C for 5min, followed by 40 cycles
(951C for 1min, 601C for 1min, 721C for 1min) and a final step of
721C for 7min. For CRHR1, primers were: sense 50-AAGGTGC
ACTACCATGTCGCA-30, antisense 50-GGTCATGAGGATGCGACG-
30 which amplified a fragment of 272bp. The PCR conditions
consisted of an initial denaturing step of 721C for 1min, followed
by 40 cycles (961C for 5min, 961C for 40s and 611C for 45s) and a
final step of 721C for 5min. For CRHR2, primers were: sense 50-
GACGCGGCACTGCTCCACAG-30, antisense 50-GCATTCCGGGTC
GTGTTGT-30, which amplified a fragment of 233bp. The PCR
conditions consisted of an initial denaturing step of 981C for 5min,
followed by 40 cycles (951C for 45s, 621C for 45s and 721C for 45s)
and a final step of 721C for 1.30min. For FasL, primers were: sense
50-ACACCTATGGAATTGTCCTGC-30, antisense 50-GACCAGAGA
GAGCTCAGATACG-30, which amplified a fragment of 311bp. The
PCR conditions consisted of an initial denaturing step of 941C for
3min, followed by 35 cycles (921C for 10s, 551C for 30s and 721C
for 60s) and a final step of 721C for 7min. A 10ml aliquot of
amplified product was electrophoresed through a 2% agarose gel,
stained with ethidium bromide, and photographed under ultra-
violet-transillumination. Total placental RNA was used as positive
control. Negative controls included substitution of reverse-
transcriptase with water (no-RT).
Indirect immunofluorescence
OvCa3 and A2780 cells grown on coverslips were washed in TBS,
and then fixed in 100% methanol at  201C for 5min. Cells were
incubated with 10% normal bovine serum (30min at rt) and then
with one of the primary antibodies overnight at 41C. Primary
antibodies against CRH (Phoenix Pharmaceuticals), CRHR1, CRHR2
and FasL (all from Santa Cruz) were diluted 1:100 plus 2% BSA. The
appropriate FITC- or TRITC-conjugated secondary antibody
(Chemicon, Temecula, CA, USA) diluted 1:100 in TBS, was added
and the cells were incubated for 1h at rt. DAPI (Molecular Probes)
was used for visualisation of the nuclei and coverslips were mounted
on glass slides. Negative controls were obtained by omission of
primary antibodies. The cells were photographed with a Leica digital
camera under an Olympus microscope.
Western blot analysis
For analysis of cellular proteins, cells were lysed using lysis buffer
(Chemicon). Lysates were boiled in sample buffer for 10min at
961C. Samples, containing 50mg protein were separated by 12%
SDS–PAGE gel, and then transferred onto a nitrocellular
membrane (Schleicher & Schuel, Sigma-Aldrich, St Louis, MO,
USA). Membranes were then blocked for 1h at rt using 5% milk
powder in TBS. Each membrane was incubated overnight at 41C
with primary anti-FasL antibody diluted 1:400 and then incubated
at rt for 1h with the appropriate peroxidase-conjugated secondary
antibody (Chemicon). Detection of proteins was carried out using
enhanced chemiluminescence (NEN Life Sciences, Boston, Massa-
chusetts, USA). To normalise for protein content, the blots were
stripped in stripping buffer (62.5mM Tris-HCl, pH 6.7, 2% SDS,
100mM b-mercaptoethanol) and stained with anti-actin antibody
(Chemicon). The concentration of FasL protein in each lysate was
normalised against actin. The intensity of the bands was quantified
using the ImageJ Imaging System, NIH, Bethesda, MD, USA.
Peripheral blood lymphocyte isolation and activation
Normal donor blood was diluted two-fold and peripheral blood
mononuclear cells were purified by Ficoll-Paque (Sigma, St Louis,
MO, USA) density-gradient centrifugation. The cells at the
interface were collected in culture in complete culture medium
(RPMI-1640, 10% FCS, 100Uml
 1 penicillin, and 50gml
 1
gentamicin, all from GibcoBRL), and incubated for 2h at 371Ci n
an atmosphere of 5% CO2 to allow adherent cells to attach to the
plastic. The supernatant containing peripheral blood lymphocytes
(PBL) was collected. To induce Fas expression, PBL were activated
by culturing in complete RPMI-1640 medium supplemented with
50Uml
 1 interleukin-2 for 3 days (Meng et al, 2004).
Apoptosis assays
OvCa3 and A2780 cells were grown in six-well plates in their
respective media with or without the presence of 100nM CRH
CRH in ovarian cancer
V Minas et al
638
British Journal of Cancer (2007) 97(5), 637–645 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s(Tocris)71mM antalarmin (gift from GP Chrousos). After 48h, the
media were changed to RPMI with 10% FCS and 10
5 activated PBL
were added to the wells for each treatment, which resulted in
target:effector cell ratios of approximately 1:20. Treatments in
co-cultures included addition of 10nM CRH7antalarmin, and
addition of 10nM CRH72mg of an anti-Fas blocking antibody
according to the manufacturer’s instructions (SM1/23, ALEXIS
Biotechnologies, Lausen, Switzerland). When the anti-Fas antibody
was used, PBL were treated with it for 1h before co-cultures. After
24h in co-culture, the wells were gently rinsed to recover the non-
adherent PBL. The latter were either cytospined (for TUNEL and
poly-caspase activation detection assay) or lysed (for caspase-8
colorimetric assay). Apoptosis was detected (i) by TUNEL assay
(terminal deoxynucleotidyl transferase-mediated dUTP nick end
labelling) (Boehringer-Mannheim) (ii) by fluorescence staining of
activated caspases using a poly-caspase activation-detection kit
(the kit stains activated caspase-1, -3, -4, -5, -6, -7, -8 and -9)
(Molecular Probes), and (iii) by a caspase-8 colorimetric assay
(R&D systems, Minneapolis, MN, USA). All three kits are
commercially available and were used according to manufacturers’
instructions. In assays (i) and (ii), DAPI was used for the
visualisation of nuclei and apoptotic cells were visualised under
an Olympus fluorescence microscope and photographed with a
Leica camera. Five random  20 microscopic fields per slide were
photographed and the number of positively fluoresced cells and
the total number of cells were counted. Each slide was
independently evaluated by two investigators. For controls, PBL
were additionally subjected to the three apoptosis assays after
cultured alone for 24 or 48h with 10 or 100nM CRH.
Cell growth analysis
Cell proliferation was evaluated by MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide) assay (Sigma) and cell
counting. For MTT assay, OvCa3 or A2780 cells were seeded in 96-
well plates and treated with 10 or 100nM CRH, or medium only for
24, 48 or 72h (five wells per condition, 10
4 cells per well). Fresh
CRH was added to the culture every 24h. At the end of the
incubation period, the MTT assay was performed according to the
manufacturer’s instructions. Plates were read at 620nm with an
ELISA microplate reader (BioRad, Hercules, CA, USA). For cell
counting, cells were grown in flasks (10
5 cells per flask) and same
treatments were performed. Cells numbers were estimated (using
Trypan blue exclusion) at 24, 48 and 72h.
Statistics
Statistical analysis was performed using the non-parametrical
Mann–Whitney U-test and the unpaired two-tailed Student’s
t-test (assuming equal variances). Only Po0.05 was considered
significant.
RESULTS
Human ovarian cancer produces the CRH, CRHR1, CRHR2
and FasL peptides
Immunohistochemistry on 47 cases of human ovarian cancer
revealed that human ovarian tumour cells produce the investigated
peptides in situ. Overall, the percentages of tumours which were
found to express one of the peptides CRH, CRHR1, CRHR2 and
FasL were 68.1, 70.2, 63.8 and 63.8%, respectively (examples of
tissues positive or negative for one of the peptides are shown in
Figure 1). Tumour advancement, as assessed by increasing tumour
stage, was associated with significantly increased immunohisto-
chemical positivity for CRH and FasL (Po0.05 between stage II
and stage IV tumours) (Table 1). This correlation was further
confirmed by IRS scoring. In this case, tumour advancement was
positively correlated with the comparatively estimated amount of
CRH or FasL produced by tumour cells (Figure 1) (Po0.05
between stage II and stage IV tumours). Furthermore, tumour
advancement was positively correlated with the percentage of
tumours simultaneously expressing CRH, CRHR1 and FasL. These
three peptides were concurrently expressed by 30% of stage II, 48%
of stage III and 66.7% of stage IV tumours, whereas the overall
percentage of tissues positive for all three peptides was 48.9%. This
difference however, was not statistically significant (Table 1).
No significant differences in the expression of the examined
molecules were detected between groups of tumours with different
histological grade or type (data not shown).
OvCa3 cells express CRH, CRHR1, FasL and A2780 express
CRH, CRHR1, CRHR2, FasL mRNAs and peptides
RT–PCR was performed in total mRNA extracted from OvCa3 and
A2780 cells, with the use of appropriate primers. Amplification of
cDNA generated bands of expected sizes, representing the
expression of the CRH, CRHR1, CRHR2 and FasL genes, with the
exception of CRHR2, which was not expressed in OvCa3 cells
(Figure 2A). Total placental mRNA was used as positive control,
since placenta expresses mRNAs of the examined genes. Omission
of reverse transcriptase served as negative control to exclude
material or genomic DNA contamination (no-RT). Immuno-
fluorescence experiments revealed the expression of the respective
peptides in both cell lines, again with the exception of CRHR2,
which was absent from OvCa3 cells (Figure 2B). Corticotropin-
releasing hormone was detected in the cytoplasm whereas CRHR1,
CRHR2 and FasL were mainly localised on the cell membranes.
Negative controls were obtained after omission of primary
antibodies.
CRH upregulates the expression of FasL in OvCa3 and
A2780 cells through CRHR1
OvCa3 and A2780 cells were incubated with CRH with or without
the presence of antalarmin, a CRHR1-specific antagonist, at
10-fold higher concentration. After 48h incubation with 10 or
100nM CRH, expression of FasL in OvCa3 cells was increased
1.7- and 2.2-fold, respectively compared to control. The respective
figures for A2780 cells were 2.3- and 2.6-fold. This effect was
specifically mediated by CRHR1, since the addition of 1mM
antalarmin completely reversed it. The experiment was performed
four times (Figure 3) (Po0.05).
CRH potentiates the ability of OvCa3 and A2780 cells to
induce Fas-mediated apoptosis of activated lymphocytes
Cytospin preparations of activated PBL co-cultured with OvCa3 or
A2780 cells in the presence or absence of CRH7antalarmin, were
subjected to TUNEL and poly-caspase assays and examined under
fluorescence microscopy. When activated PBL were cultured for
24h with FasL-expressing OvCa3 or A2780 cells in the absence of
CRH, a small percentage of the lymphocytes underwent apoptosis
(1372% in TUNEL and 1073% in poly-caspase assay for co-
cultures with OvCa3, 1472 and 1373%, respectively for
co-cultures with A2780) (Figure 4C, G and Figure 5C, G). However,
when activated PBL were cultured with OvCa3 or A2780 cells,
which were pre-incubated for 48h with 100nM CRH, in the
continuous presence of 10nM CRH, significantly higher percen-
tages of the lymphocytes underwent apoptosis (3474% in TUNEL
and 3572% in poly-caspase assay for co-cultures with OvCa3,
3572 and 3371%, respectively for co-cultures with A2780)
(Figures 4D, G and 5D, G, respectively) (Po0.05). This effect
was mediated by CRHR1, since the addition of 1mM antalarmin
reduced apoptosis to control amounts (Figures 4E, G and 5E, G).
To establish a role for FasL in PBL apoptosis, an anti-Fas blocking
CRH in ovarian cancer
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santibody was employed. Addition of 2mg of the antibody, blocked
the effect of CRH-treated ovarian cancer cells on PBL apoptosis
(672% apoptotic PBL in TUNEL and 773% in poly-caspase assay
for co-cultures with OvCa3, 771% in TUNEL and 773% in poly-
caspase for co-cultures with A2780) (Figures 4F, G and 5F, G).
Finally, to exclude the possibility of a potent cytotoxic effect of
CRH against activated PBL, the latter were cultured alone710 or
100nM CRH for 24 or 48h. Basic levels of PBL apoptosis after 24h
in culture were 471.5% in TUNEL and 571% in poly-caspase
assay (Figures 4A, G and 5A, G). Addition of 10nM CRH increased
apoptosis of PBL after 24h in culture (1271% in TUNEL and
10.572% in poly-caspase assay) (Figures 4B, G and 5B, G)
(Po0.05). Results obtained with different CRH concentrations (10
or 100nM) and at different time intervals (24 or 48h) did not differ
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Figure 1 Immunohistochemical expression of CRH, CRHR1, CRHR2 and FasL in ovarian cancer tissue. (A–L) Representative photos of cases, which
expressed or did not express the investigated peptides. CRH was immunolocalised in tumour cells in 68.1% of the cases examined (A, B), whereas the rest
(31.9%) did not express the peptide (C). CRHR1 was expressed in 70.2% of cases (D, E) and absent from 29.8% (F). CRHR2 was expressed in 63.8% (G,
H) of cases and absent from 36.2% (I). Finally, 63.8% of the cases were positive for FasL (J, K) and 36.2% were negative (L). Lens  10 (A, C, D, F, G, I, J,
L),  40 (B, E, H, K). (M) Staining intensity was determined by the semiquantitative immunohistochemical IRS. There was a statistically significant increase
in CRH and FasL expression between stage II and stage IV tumours. Data represent mean7s.e. (*Po0.05).
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ssignificantly (data not shown). In all cases, apoptosis was
significantly lower than in co-cultures with CRH-treated ovarian
cancer cells (Po0.05). All experiments were performed four times
(Po0.05).
Following the same treatments, activated PBL were lysed and
subjected to caspase-8 colorimetric assay. Results were similar
with those from the two aforementioned assays (Figure 5H). The
experiment was performed four times (Po0.05).
CRH does not affect growth of OvCa3 or A2780 cells
To investigate the potential effect of CRH on ovarian cancer cell
growth, MTT assay and cell counting were performed. Cortico-
tropin-releasing hormone at 10 or 100nM had no effect on cell
growth after 24, 48 or 72h of treatment compared to medium alone
(control) (Figure 6). All experiments were performed four times.
DISCUSSION
Our study indicates that intratumoral expression of CRH and FasL
is associated with advanced tumour stage in ovarian cancer. The
expression of the two peptides was significantly higher in stage IV
compared to stage II tumours. The percentage of tumours
simultaneously expressing CRH, CRHR1 and FasL was higher in
stage IV compared to stage II tumours, although this difference
was not statistically significant. In addition, we present data that
might offer an explanation on the association of intratumoral
CRH with tumour advance. We found that CRH upregulates the
expression of FasL in two human ovarian cancer cell lines (OvCa3
and A2780), thereby potentiating their ability to induce Fas-
mediated apoptosis of activated PBL. Finally, CRH had no effect on
growth of OvCa3 or A2780 cells.
Corticotropin-releasing hormone is the principal regulator of
the stress response in mammals (Bale and Vale, 2004). Outside the
central nervous system, CRH is produced in several peripheral
tissues, where it acts as an autocrine and/or paracrine regulator
of various cellular functions (Boorse and Denver, 2006). Cortico-
tropin-releasing hormone mRNA and peptide have been detected
in both human and rat normal ovaries. More specifically,
immunoreactive CRH (irCRH) and its binding sites have been
localised in thecal and stromal cells of rat and human ovaries and
in human follicular fluid (Mastorakos et al, 1993, 1994). Type 1 (CRHR1)
and type 2 (CRHR2) CRH receptor mRNAs have also been detected
in corpus luteum (Muramatsu et al, 2001). It is currently suggested
that the role of the locally expressed CRH system in normal ovary,
is to regulate—more likely suppress—ovarian steroidogenesis
(Calogero et al, 1996; Ghizzoni et al, 1997; Erden et al, 1998).
Table 1 Percentages of ovarian cancer tumours expressing CRH,
CRHR1, CRHR2 or FasL peptides, sorted by tumour stage
Peptide(s) Tumour stage Positive cases Negative cases
CRH II 40% (4/10) 60% (6/10)
III 72% (18/25) 28% (7/25)
IV 83.3% (10/12)
a 16.7% (2/12)
CRHR1 II 60% (6/10) 40% (4/10)
III 72% (18/25) 28% (7/25)
IV 75% (9/12) 25% (3/12)
CRHR2 II 50% (5/10) 50% (5/10)
III 68% (17/25) 32% (8/25)
IV 66.7% (8/12) 33.3% (4/12)
FasL II 40% (4/10) 60% (6/10)
III 64% (16/25) 36% (9/25)
IV 83.3% (10/12)
a 16.7% (2/12)
CRH/CRHR1/FasL II 30% (3/10) 70% (7/10)
III 48% (12/25) 52% (13/25)
IV 66.7% (8/12) 33.3% (4/12)
aPercentage of stage IV tumours expressing CRH or FasL was significantly higher than
that of stage II tumours (Po0.05).
CRH (244 bp)
CRHR1 (272 bp)
CRHR2 (230 bp)
FasL (311 bp)
OvCa3 A2780
CRH
CRHR1
CRHR2
FasL
Negative
Placenta
OvCa3
A2780
No-RT
A
B
Figure 2 Expression of CRH, CRHR1, CRHR2 and FasL mRNAs and
peptides in OvCa3 and A2780 cells. (A) RT–PCR was performed in total
mRNA extracted from OvCa3 and A2780 cells. Amplification of cDNA
generated bands of expected sizes, representing the expression of the CRH
(244bp), CRHR1 (272bp), CRHR2 (230bp) and FasL (311bp) genes, with
the exception of CRHR2, which was not expressed in OvCa3 cells. Total
placental mRNA was used as positive control. Omission of reverse
transcriptase served as negative control to exclude material or genomic
DNA contamination (no-RT). (B) Immunofluorescence experiments
revealed the expression of CRH, CRHR1, CRHR2 and FasL peptides,
again with the exception of CRHR2 which was not detected in OvCa3
cells. CRH was detected in the cytoplasm whereas CRHR1 and FasL were
localised mainly on the cell membrane. For negative controls, primary
antibodies were omitted. Lens  40.
CRH in ovarian cancer
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sCorticotropin-releasing hormone and its receptors have been
detected in a number of primary human tumours. Corticotropin-
releasing hormone is expressed in melanoma (Sato et al, 2002),
pheochromocytoma, ovarian cancer (Suda et al, 1986) and breast
cancer (Ciocca et al, 1990). Corticotropin-releasing hormone
receptors have been detected in melanoma (Funasaka et al,
1999), in pancreatic and central and peripheral nervous system
tumours (Reubi et al, 2003). The present study confirms the
expression of CRH and reports for the first time the expression of
CRH receptors in ovarian cancer in situ. Therefore, CRH may act
in a paracrine and/or autocrine way to modulate various functions
of ovarian tumour cells. Furthermore, this study associates the
expression of CRH with tumour advancement to higher stages,
thus proposing that the tumour might benefit from CRH secretion.
In addition to CRH, stage IV tumours upregulated FasL. The
latter is currently considered an important part of tumours’
defences against immune attack. In parallel to FasL expression,
cancer cells often display resistance to Fas-mediated apoptosis and
therefore ‘the Fas counterattack’ concept was introduced to
describe the modulation of the Fas–FasL system by tumour cells
to favour their immune privilege (OConnell et al, 1999).
The present results are in agreement with previous studies
reporting the expression of FasL in different tumours and the
association of the molecule with the disease’s clinical course. FasL
has been detected in several tumours of varying origin, including
colon (Okada et al, 2000), breast (Mottolese et al, 2000; Reimer
et al, 2000), liver (Ito et al, 2000), gastric (Zheng et al, 2003) and
lung carcinoma (Niehans et al, 1997; Volm and Koomagi, 2000),
astrocytoma (Saas et al, 1997), esophageal (Shibakita et al, 1999),
renal (Kim et al, 2000) and ovarian tumours (Munakata et al, 2000;
van Haaften-Day et al, 2003). Most of the aforementioned reports
showed that disease progression was associated with progressively
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expression in OvCa3 and A2780 cells. This effect was mediated by CRHR1,
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Figure 4 TUNEL assay in activated lymphocytes after co-culturing with
OvCa3 or A2780 cells. (A–F) Representative TUNEL assay photos of PBL
after 24h culturing in various conditions. Activated PBL cultured alone for
24h showed only limited apoptosis (A). In the presence of 10nM CRH,
PBL apoptosis was moderately increased (B). Similarly, moderate levels of
PBL apoptosis occurred after co-culturing with OvCa3 or A2780 cells (C).
Activated PBL cultured with OvCa3 or A2780 cells primed with 100nM
CRH for 48h, then with the continuous presence of 10nM CRH for 24h,
showed high levels of apoptosis (D). Activated PBL cultured with OvCa3
or A2780 cells primed with 100nM CRHþ1mM antalarmin for 48h, then
with 10nM CRHþ100nM antalarmin for 24h, reverted the effects of CRH
(E). Similarly, addition of an anti-Fas blocking antibody in co-cultures with
CRH-treated cells, reverted the effects of CRH (F). (G) Quantitation of
results. Data represent mean7s.e. (n¼4) (*Po0.05).
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sincreased expression of FasL. In some types of the examined
tumours, including the ovarian, intratumoral lymphocytes showed
either increased apoptosis or decreased density within cases which
expressed FasL (O’Connell et al, 1999).
An elaborate study by Zhang et al (2003) further confirmed and
revealed the significance of the intensity of immune attack to the
progression of ovarian cancer. The authors concluded that the
presence of tumour-infiltrating T cells in ovarian carcinoma cases
correlates with improved clinical outcome. Reduced immune
response against the tumour or increased tumour counterattack, as
evidenced by the absence of intratumoral T cells in islets, was
associated with low 5-year overall survival rate (Zhang et al, 2003).
In our study, insufficient clinical data and restricted number of
cases did not allow association of the immunohistochemical results
with clinical outcome. Nevertheless, a significant correlation
between FasL expression and advanced tumour stage is reported.
Although no alteration was observed in the expression of
CRHRs among the three stage-groups of tumours, more stage IV
than stage II tumours simultaneously expressed the CRH, CRHR1
and FasL peptides. This difference was not statistically significant
due to the small number of cases. Nevertheless, we assumed that
there could be a functional interrelation between the three
peptides. To explore this hypothesis, the ovarian cancer cell lines
OvCa3 and A2780 were employed. OvCa3 cells were found to
express CRH, CRHR1 and FasL, but not CRHR2 transcripts and
peptides, whereas A2780 expressed all of the above transcripts and
peptides. In both cell lines, CRH induced FasL through CRHR1.
This was in accord with previous reports on rat pheochromo-
cytoma PC12 cancer cells (Dermitzaki et al, 2002), and on EVT,
a particular cell type sharing similarities with cancer cells
(Makrigiannakis et al, 2001). This effect of CRH was further found
to have a role in mediating an attack of OvCa3 and A2780 cells
against activated PBL, again in agreement with the case of EVT
(Makrigiannakis et al, 2001). When PBL were placed in co-cultures
with OvCa3 or A2780 cells in the presence of CRH, the number of
PBL, which underwent apoptosis significantly increased compared
to co-cultures without CRH, or with CRH and antalarmin. We
suggest that apoptosis of PBL was mainly owed to Fas–FasL
interaction for the following reasons: Addition of an anti-Fas
blocking antibody reverted the effect of CRH-treated ovarian
cancer cells, by significantly reducing the numbers of apoptotic
PBL. Furthermore, CRH alone induced low levels of PBL apoptosis,
comparable to those measured in co-cultures with ovarian cancer
cells without any additives. Finally, in all conditions, the enzymatic
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Figure 5 Poly-caspase assay and caspase-8 colorimetric assay in activated lymphocytes after co-culturing with OvCa3 or A2780 cells. (A–F)
Representative poly-caspase assay photos of PBL after 24h culturing in various conditions. Poly-caspase assay confirmed the results obtained from TUNEL
assay, as described in Figure 4. (G) Quantitation of results. Data represent mean7s.e. (n¼4) (*Po0.05). (H) Caspase-8 enzymatic activity in activated PBL
cultured as described above. Results were similar to those described in Figures 4G and 5G. Data represent mean7s.e. (expressed as O.D. units, optical
density) (n¼4) (*Po0.05).
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sactivity of caspase-8 (a key component of the Fas–FasL apoptotic
pathway) in PBL lysates was in accordance with levels of PBL
apoptosis.
The ability of ovarian cancer cells to induce Fas-mediated
apoptosis to lymphocytes has been previously reported by a
number of studies using different experimental approaches
(Rabinowich et al, 1998; Abrahams et al, 2003; Meng et al,
2004). In particular, Meng et al (2004) found that lysophosphatidic
acid stimulates the expression of FasL in OvCa3 cells. Similarly to
the present study, the authors showed that stimulated tumour cells
induced apoptosis of isolated T lymphocytes more effectively than
their unstimulated controls (Meng et al, 2004). Additional factors,
which regulate FasL in tumour cells, include oestrogen and the
anti-oestrogen factor tamoxifen tested on human breast cancer
cells (Mor et al, 2000), and the bacterial polysaccharide exotoxin
CM101 tested on murine melanoma cells (Yakes et al, 2000). The
results of the present study suggest that tumour-produced CRH
might be an autocrine–paracrine factor, which together with
others, modulates the expression of FasL in ovarian cancer. Since a
large proportion of ovarian tumours were found to express CRHR1
(70.2%), secretion of CRH might considerably improve tumour’s
resistance to immune attack and thus favour its survival and
progression. These observations are of particular importance,
since growth assays failed to reveal an anti-proliferative effect of
CRH on ovarian cancer cells, which is in contrast with what has
been reported on human endometrial and breast cancer cells
(Graziani et al, 2002, 2007). Of note, CRH-stimulated angiogenesis
and promoted tumour growth in vivo in a model of mice
inoculated with human epithelial tumour cells (Arbiser et al,
1999). Thus, the effect of CRH on tumour growth appears to be
tissue-specific and the final result in vivo might differ from the
observed effects in vitro due to the contribution of several factors.
In their study, Reubi et al (2003) detected CRH receptors in
specific tumours and expressed the very promising hypothesis that
these receptors might be used as targets for long-term CRH
therapy. However, our lack of knowledge on the role of CRH in
cancer biology, limits our leeway for testing CRH antagonists
against specific and vital molecular functions of the tumour. Non-
peptidic CRHR1 antagonists have been tested in experimental
animals. It has been shown that chronic use of CRHR1 antagonists
in rats has no serious adverse effects (Grammatopoulos and
Chrousos, 2002). It is tempting to speculate that in advanced stage
ovarian carcinoma, chronic use of a CRHR1 antagonist could
reduce tumour immune defence mechanisms by downregulating
intratumoral FasL expression. As a result, cancer cells would be
recognised and attacked by the immune system. In addition, the
present results suggest that use of such substances would be
unlikely to directly affect the proliferation rate of the tumour cells.
Therefore, the observations reported here introduce novel insight
into how such molecules could be used against cancer. This
hypothesis is currently under investigation by our research group.
In summary, we found that CRH, its receptors CRHR1 and
CRHR2, and the proapoptotic molecule FasL are produced by
human ovarian tumour cells in situ. Expression of CRH and FasL
were positively associated with higher tumour stage. We propose
that tumour CRH acts in a paracrine–autocrine way to favour
survival and progression of the tumour by promoting its immune
privilege, whereas it has no direct effect on tumour cells growth
rate. Indeed, CRH acted on the ovarian cancer cells OvCa3 and
A2780, through CRHR1, to upregulate the expression of FasL and
thus potentiate the ability of the cells to induce Fas-mediated
apoptosis of activated PBL. Our study sets the initiative for the
consideration of CRHR1 antagonists in an effort to reduce tumour
immune defenses.
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